 SHANGHAI and GAITHERSBURG, Md., May 13, 2021 PRNewswire -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced that I-Mab has been selected for inclusion in the MSCI China All Shares Index, following MSCIs most recent semi-annual review. 